Clover Corporation has entered FY27 with stronger margins, no interest-bearing debt and revenue momentum after reporting a 50% rise in FY26 NPAT. The company expects first-half FY27 revenue of about $60 million and says full-year revenue and earnings could outperform FY26 if current conditions persist.
- FY26 revenue rose 13.3% to $97.4 million
- NPAT increased 50% to $10.5 million
- Gross margin expanded to 35.5%
- Balance sheet held $7.2 million in cash with no interest-bearing liabilities
- FY27 first-half revenue expected to be around $60 million
FY26 profit growth exceeds revenue growth
Clover Corporation Limited (ASX:CLV) has put a sharper edge on its growth story, with FY26 net profit after tax rising 50% to $10.5 million while revenue increased 13.3% to $97.4 million. The result was supported by a substantial improvement in gross margin, which rose to 35.5% from 30.5%.
EBITDA climbed 39% to $17.0 million, lifting the EBITDA margin to 17.5% from 14.2%. Clover said the improvement reflected sales growth, a more favourable customer and product mix, vertical integration across its supply chain and lower operating costs as a proportion of sales. Revenue also came in ahead of the company’s previous $92 million to $96 million guidance range.
The figures extend the trajectory outlined in the September FY26 results, which reported the same $97.4 million revenue outcome and a 50% lift in attributable profit. Clover declared a final fully franked dividend of 1.25 cents per share, while earnings per share increased to 6.3 cents from 4.2 cents.
Inventory investment reshapes the balance sheet
The balance sheet remains debt-free, but the cash position moved lower as Clover built inventory. Cash stood at $7.2 million at 31 July 2026, down from $8.7 million a year earlier, while inventory rose by $19.8 million to $43.9 million.
Management described the stock build as a strategic decision to secure ARA and fish oil supplies against indicative customer demand. Net working capital increased by $7.5 million to $49.8 million. That investment was partly offset by stronger earnings and lower trade receivables, which fell by $7.8 million to $17.3 million.
ARA demand and CholineXcel drive product expansion
Clover highlighted stronger demand from infant-formula customers for its ARA powders, while DHA growth is being supported by non-allergenic products, higher fortification levels and plant-based powders. The company said customer engagement for ARA was positive entering FY27, with inventory now considered appropriate for the expected demand outlook.
CholineXcel remains an earlier-stage growth project. Clover said its patent had been registered, a PCT application had been lodged and commercial packaging options were being developed. Packaging equipment is expected to be operational in the fourth quarter of FY27, while the company has begun reviewing larger-scale manufacturing through tolling, joint venture and acquisition options. The product is being targeted initially at infant formula and nutraceutical applications, following the CholineXcel patent progress reported in earlier company coverage.
US nutraceutical expansion adds cost before scale
Clover has established a dedicated resource to develop the US nutraceutical market, which it describes as the world’s largest nutraceutical market. The strategy is intended to use Clover’s encapsulation technologies and products such as Gelphorm to build a platform for wider US business development.
The company cautioned that business development costs will be expensed as incurred and are expected to increase gradually over the next two to three years as the strategy develops. In New Zealand, the Melody Dairies facility is operating near full capacity, while Clover continues to assess ways to lift output and reduce costs. In Ecuador, tuna oil accounted for 30% of total raw-material inputs in FY26, with further supply negotiations and possible capacity gains under consideration.
FY27 outlook rests on demand and supply execution
Clover expects first-half FY27 revenue to be around $60 million. It said full-year revenue and earnings should outperform FY26 if demand momentum continues, supply chains remain stable and operational efficiencies are captured. The statement is explicitly conditional, leaving inventory management, raw-material availability and the pace of margin improvement as important tests of the forecast.
Shareholders also recorded strong support across the formal business, including the remuneration report, the re-election of Ian Glasson and Toni Brendish, the election of Brett Hewlett and the Managing Director’s performance-rights resolution. The presentation does not state the resolutions as formally carried, but the listed poll figures show between 80.1% and 83.3% of votes cast in favour across those items.
Bottom Line?
The next test is whether the $60 million first-half FY27 revenue expectation can be delivered without another disproportionate build in inventory or a squeeze on cash.
Questions in the middle?
- Can Clover convert the stronger ARA demand outlook into sales while keeping inventory at a sustainable level?
- How quickly will CholineXcel move from patent and packaging development to customer orders and scaled production?
- Will US nutraceutical investment generate enough commercial traction to offset the additional costs expected over the next two to three years?